정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1703 | Terminated | Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001) | Coronavirus Disease (COVID-19) | Biological: V590 Other: Placebo |
Phase 1 | Merck Sharp & Dohme Corp. | INDUSTRY | 232 | All | 18 Years | Celerion ( Site 0002), Tempe, Arizona, United States Clinical Pharmacology of Miami ( Site 0003), Miami, Florida, United States QPS Miami Research Associates ( Site 0005), South Miami, Florida, United States Bio-Kinetic Clinical Applications (QPS) ( Site 0006), Springfield, Missouri, United States Celerion ( Site 0001), Lincoln, Nebraska, United States Alliance for Multispecialty Reseach, LLC ( Site 0004), Knoxville, Tennessee, United States Worldwide Clinical Trials ( Site 0007), San Antonio, Texas, United States |
| 1702 | Active, not recruiting | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | SARS-CoV-2 | Biological: Biological: mRNA-1273 Biological: Placebo Biological: mRNA-1273.351 |
Phase 2 | ModernaTX, Inc., Biomedical Advanced Research and Development Authority | INDUSTRY | 660 | All | 18 Years | Meridian Clinical Research, Savannah, Georgia, United States Alliance for Multispecialty Research, Newton, Kansas, United States Alliance for Multispecialty Research, Kansas City, Missouri, United States Meridian Clinical Research, Norfolk, Nebraska, United States Trial Management Associates, Wilmington, North Carolina, United States Meridian Clinical Research, Dakota Dunes, South Dakota, United States Benchmark Research, Austin, Texas, United States Benchmark Research, San Angelo, Texas, United States |
| 1701 | Not yet recruiting | Dose-finding Study for AdimrSC-2f Vaccine | COVID-19 | Biological: AdimrSC-2f | Phase 2 | Adimmune Corporation | INDUSTRY | 240 | All | 18 Years ~ 60 Years | University Gadjah Mada Academic Hospital, Selmen, Yogyakarta, Indonesia |
| 1700 | Recruiting | Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19 | Covid19 | Drug: XVR011 Drug: Normal saline |
Phase 2 | ExeVir Bio BV | INDUSTRY | 279 | All | 18 Years | Investigative Site, Ghent, Belgium Investigative Site, Liege, Belgium Investigative site, Mechelen, Belgium Investigative site, Milano, Italy Investigative Site, Roma, Italy |
| 1699 | Recruiting | Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19 | COVID-19 | Drug: Melatonin Drug: Placebo |
Phase 2 | State University of New York at Buffalo, National Center for Advancing Translational Science (NCATS) | OTHER | 50 | All | 18 Years | University at Buffalo, Buffalo, New York, United States |
| 1698 | Active, not recruiting | Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19 | COVID-19 Infection | Drug: Colchcine | Phase 3 | Asociacion Instituto Biodonostia | OTHER | 752 | All | 18 Years ~ 99 Years | Biodonostia Health Research Institute, San Sebastian, Guipuzcoa, Spain |
| 1697 | Completed | Double Therapy With IFN-beta 1b and Hydroxychloroquine | COVID | Drug: Interferon Beta-1B Drug: Hydroxychloroquine |
Phase 2 | The University of Hong Kong | OTHER | 60 | All | 18 Years | The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong |